Go Pro
→ CODE RED: AI Meltdown Imminent? (From Paradigm Press) (Ad)tc pixel Free LSTA Stock Alerts

Lisata Therapeutics (LSTA) Financials

Lisata Therapeutics logo
$1.67 -0.45 (-21.23%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$1.72 +0.05 (+2.99%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Lisata Therapeutics

Annual Income Statements for Lisata Therapeutics

This table shows Lisata Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -55 -81 -33 23 -16 -19 -8.15 -27 -54 -21 -20
Consolidated Net Income / (Loss)		 -55 -81 -33 22 -16 -19 -8.14 -27 -54 -21 -20
Net Income / (Loss) Continuing Operations		 -55 -81 -31 -16 -16 -19 -8.14 -27 -54 -21 -20
Total Pre-Tax Income 		-56 -98 -31 -28 -16 -19 -19 -29 -57 -23 -21
Total Operating Income		 -58 -114 -30 -28 -17 -20 -19 -29 -58 -26 -22
Total Gross Profit		 2.26 2.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
Total Revenue		 18 22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
Operating Revenue		 18 22 - - - - - - - 0.00 1.00
Total Cost of Revenue		 16 20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 60 116 30 28 17 20 19 29 58 26 23
Selling, General & Admin Expense		 31 30 13 12 9.39 9.30 9.89 11 14 13 12
Research & Development Expense		 29 24 17 16 7.59 11 9.25 18 43 13 11
Total Other Income / (Expense), net		 2.17 16 -1.76 -0.11 0.82 0.74 0.13 0.08 0.90 2.54 1.63
Interest & Investment Income		 - - - - - - 0.13 0.15 1.05 2.72 1.88
Other Income / (Expense), net		 2.93 18 0.02 0.27 0.82 0.74 0.00 -0.08 -0.16 -0.19 -0.26
Income Tax Expense		 -0.10 -17 0.00 -12 - 0.00 -11 -1.51 -2.48 -2.33 -0.80
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.59 -0.12 -0.65 -0.75 -0.00 0.01 0.01 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($1.68) ($16.67) ($4.99) $2.56 ($1.67) ($1.88) ($0.53) ($7.45) ($10.47) ($2.58) ($2.40)
Weighted Average Basic Shares Outstanding		 32.76M 4.85M 6.55M 8.97M 9.69M 10.33M 15.44M 3.69M 5.18M 8.07M 8.33M
Diluted Earnings per Share		 ($1.68) ($16.67) ($4.99) - ($1.67) ($1.88) ($0.53) ($7.45) ($10.47) ($2.58) ($2.40)
Weighted Average Diluted Shares Outstanding		 32.76M 4.85M 6.55M 8.97M 9.69M 10.33M 15.44M 3.69M 5.18M 8.07M 8.33M
Weighted Average Basic & Diluted Shares Outstanding		 32.76M 4.85M 6.55M 9.55M 9.69M 10.33M 15.44M 60.53M 8.00M 8.31M 9.03M

Quarterly Income Statements for Lisata Therapeutics

This table shows Lisata Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2025 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -5.26 -5.37 -5.40 -5.04 -4.93 -1.21 -4.72 -4.66 -4.25 -4.49
Consolidated Net Income / (Loss)		 -5.26 -5.37 -5.40 -5.04 -4.93 -1.21 -4.72 -4.66 -4.25 -4.49
Net Income / (Loss) Continuing Operations		 -5.26 -5.37 -5.40 -5.04 -4.93 -1.21 -4.72 -4.66 -4.25 -4.49
Total Pre-Tax Income 		-5.26 -5.37 -6.20 -5.04 -4.93 -1.38 -5.69 -4.66 -4.25 -4.88
Total Operating Income		 -5.96 -6.03 -6.60 -5.52 -5.34 -0.75 -5.85 -4.87 -4.41 -4.94
Total Gross Profit		 0.00 - 0.00 0.00 0.00 0.17 0.00 0.07 0.00 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 0.17 0.00 0.07 0.00 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Operating Expenses		 5.96 6.03 6.60 5.52 5.34 0.92 5.85 4.94 4.41 4.94
Selling, General & Admin Expense		 2.58 3.01 3.36 2.92 2.79 1.35 3.25 2.69 2.46 3.74
Research & Development Expense		 3.38 3.01 3.24 2.60 2.54 -0.44 2.60 2.25 1.96 1.20
Total Other Income / (Expense), net		 0.70 0.66 0.40 0.48 0.41 -0.63 0.16 0.21 0.17 0.07
Interest & Investment Income		 0.71 0.67 0.59 0.49 0.45 -0.73 0.27 0.22 0.18 0.12
Other Income / (Expense), net		 -0.01 -0.01 -0.19 -0.01 -0.05 0.10 -0.11 -0.01 -0.02 -0.05
Income Tax Expense		 0.00 - -0.80 0.00 0.00 -0.16 -0.96 0.00 0.00 -0.39
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($0.65) ($0.66) ($0.65) ($0.61) ($0.59) ($0.06) ($0.55) ($0.54) ($0.49) ($0.50)
Weighted Average Basic Shares Outstanding		 8.14M 8.07M 8.29M 8.31M 8.32M 8.69M 8.60M 8.61M 8.74M 9.01M
Diluted Earnings per Share		 ($0.65) ($0.66) ($0.65) ($0.61) ($0.59) ($0.06) ($0.55) ($0.54) ($0.49) ($0.50)
Weighted Average Diluted Shares Outstanding		 8.14M 8.07M 8.29M 8.31M 8.32M 8.69M 8.60M 8.61M 8.74M 9.01M
Weighted Average Basic & Diluted Shares Outstanding		 8.14M 8.31M 8.31M 8.32M 8.39M 9.03M 8.60M 8.76M 8.82M 9.11M

Annual Cash Flow Statements for Lisata Therapeutics

This table details how cash moves in and out of Lisata Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2025
Net Change in Cash & Equivalents		 -27 1.14 -5.61 19 -24 3.73 2.48 8.14 7.51 -9.56 -0.25
Net Cash From Operating Activities		 -47 -39 -24 -21 -20 -19 -8.82 -22 -21 -20 -16
Net Cash From Continuing Operating Activities		 -47 -39 -28 -20 -20 -19 -8.82 -22 -21 -20 -16
Net Income / (Loss) Continuing Operations		 -55 -81 -31 -16 -16 -19 -8.14 -27 -54 -21 -17
Consolidated Net Income / (Loss)		 -55 -81 -33 22 -16 -19 -8.14 -27 -54 -21 -17
Depreciation Expense		 2.19 2.69 0.45 0.37 0.23 0.07 0.06 0.06 0.07 0.19 0.15
Amortization Expense		 - - - - - 0.23 0.31 2.51 0.79 -0.96 -0.08
Non-Cash Adjustments To Reconcile Net Income		 8.17 54 2.36 2.52 1.31 1.30 1.27 2.01 33 2.04 1.85
Changes in Operating Assets and Liabilities, net		 -1.79 -15 0.22 -6.95 -5.35 -1.12 -2.32 0.65 -0.83 -0.46 -1.29
Net Cash From Investing Activities		 -11 3.80 -2.85 41 -4.71 21 -7.28 -55 29 10 15
Net Cash From Continuing Investing Activities		 -11 3.80 -1.10 41 -4.71 21 -7.28 -55 29 10 15
Purchase of Property, Plant & Equipment		 -3.66 -3.19 -1.10 -0.14 -0.13 0.00 -0.02 -0.06 -0.29 - -0.03
Purchase of Investments		 -8.04 -6.08 0.00 -60 -70 -33 -35 -180 -90 -98 -9.18
Sale and/or Maturity of Investments		 0.91 13 0.00 34 63 54 28 125 122 109 24
Net Cash From Financing Activities		 31 37 21 -0.93 0.82 1.18 19 85 -0.22 0.39 0.60
Net Cash From Continuing Financing Activities		 31 37 17 -0.86 0.82 1.18 19 85 -0.22 0.39 0.60
Issuance of Common Equity		 17 36 12 5.70 1.03 1.31 19 86 0.04 0.32 0.84
Other Financing Activities, net		 1.99 0.00 -0.07 -0.35 -0.05 -0.13 -0.15 -0.22 -0.27 0.06 -0.25
Effect of Exchange Rate Changes		 - - - - - - - 0.00 -0.01 -0.02 0.01

Quarterly Cash Flow Statements for Lisata Therapeutics

This table details how cash moves in and out of Lisata Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2025 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Net Change in Cash & Equivalents		 8.74 -9.84 -0.79 6.49 -8.78 2.83 4.01 -3.38 2.16 -2.90
Net Cash From Operating Activities		 -3.58 -4.07 -7.03 -5.28 -2.52 -1.12 -5.40 -3.96 -3.34 -3.08
Net Cash From Continuing Operating Activities		 -3.58 -4.07 -7.03 -5.28 -2.52 -1.12 -5.40 -3.96 -3.34 -3.08
Net Income / (Loss) Continuing Operations		 -5.26 -5.37 -5.40 -5.04 -4.93 -1.21 -4.72 -4.66 -4.25 -4.49
Consolidated Net Income / (Loss)		 -5.26 -5.37 -5.40 -5.04 -4.93 -1.21 -4.72 -4.66 -4.25 -4.49
Depreciation Expense		 0.05 0.05 0.05 0.05 0.04 0.01 0.04 0.04 0.04 0.00
Amortization Expense		 -0.28 -0.25 -0.15 -0.13 -0.09 0.30 -0.04 -0.02 -0.01 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.31 0.47 0.55 0.24 0.36 0.71 0.53 0.24 0.23 0.36
Changes in Operating Assets and Liabilities, net		 1.61 1.03 -2.07 -0.39 2.10 -0.93 -1.21 0.44 0.65 1.04
Net Cash From Investing Activities		 12 -5.71 6.44 12 -6.31 3.24 9.43 0.51 5.15 0.00
Net Cash From Continuing Investing Activities		 12 -5.71 6.44 12 -6.31 3.24 9.43 0.51 5.15 0.00
Purchase of Property, Plant & Equipment		 - - 0.00 - - -0.03 -0.03 - - 0.00
Purchase of Investments		 -17 -21 -19 -9.69 -15 35 -5.06 -4.13 - 0.00
Sale and/or Maturity of Investments		 29 15 25 21 9.16 -32 15 4.63 5.15 0.00
Net Cash From Financing Activities		 -0.01 0.02 -0.14 0.03 - 0.71 -0.02 0.06 0.35 0.18
Net Cash From Continuing Financing Activities		 -0.01 0.02 -0.14 0.03 - 0.71 -0.02 0.06 0.35 0.18
Issuance of Common Equity		 - 0.02 0.00 0.03 - 0.81 0.21 0.07 0.35 0.00
Other Financing Activities, net		 -0.01 - -0.14 - - -0.10 -0.24 -0.01 - 0.18
Effect of Exchange Rate Changes		 - -0.08 -0.06 0.03 0.04 0.00 0.00 0.01 0.00 0.01

Annual Balance Sheets for Lisata Therapeutics

This table presents Lisata Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2025
Total Assets		 57 54 63 45 27 36 97 73 55 18 18
Total Current Assets		 29 25 61 44 26 35 96 72 54 18 18
Cash & Equivalents		 20 7.08 29 10 14 17 25 32 23 16 16
Prepaid Expenses		 3.48 1.90 1.31 1.05 0.82 0.76 1.21 2.65 3.39 1.75 1.75
Plant, Property, & Equipment, net		 17 0.71 0.26 0.17 0.10 0.06 0.06 0.30 0.18 0.02 0.02
Total Noncurrent Assets		 11 28 1.72 0.31 1.08 0.61 0.76 0.86 0.60 0.02 0.02
Other Noncurrent Operating Assets		 0.98 1.58 1.72 0.31 1.08 0.61 0.76 0.53 0.33 0.02 0.02
Total Liabilities & Shareholders' Equity		 57 54 63 45 27 36 97 73 55 18 18
Total Liabilities		 34 30 13 7.13 6.60 3.76 5.01 6.71 6.80 3.14 3.14
Total Current Liabilities		 21 21 9.31 5.62 5.98 3.51 4.52 6.38 6.59 3.07 3.07
Accounts Payable		 4.11 3.91 1.34 0.76 1.49 1.02 1.93 2.66 2.42 1.02 1.02
Accrued Expenses		 6.20 2.66 7.81 4.86 4.49 2.49 2.59 3.73 4.17 2.05 2.05
Total Noncurrent Liabilities		 13 8.87 3.87 1.51 0.62 0.25 0.49 0.33 0.21 0.07 0.07
Other Noncurrent Operating Liabilities		 0.56 0.39 3.87 1.51 0.62 0.25 0.49 0.33 0.21 0.07 0.07
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 23 4.07 50 37 21 32 92 66 48 15 15
Total Preferred & Common Equity		 24 4.88 51 38 21 32 92 67 48 15 15
Total Common Equity		 24 4.88 51 38 21 32 92 67 48 15 15
Common Stock		 397 410 433 436 439 459 546 575 577 580 580
Retained Earnings		 -372 -405 -382 -398 -417 -426 -453 -507 -528 -565 -565
Treasury Stock		 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.00 -0.03 -0.03 0.00 -0.01 -0.07 -0.03 -0.04 -0.04 -0.04
Noncontrolling Interest		 -0.43 -0.82 -0.32 -0.27 -0.26 -0.25 -0.25 -0.25 -0.25 -0.25 -0.25

Quarterly Balance Sheets for Lisata Therapeutics

This table presents Lisata Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 58 48 43 38 29 25 22 14
Total Current Assets		 57 48 42 38 29 25 22 14
Cash & Equivalents		 32 22 28 20 20 17 19 13
Prepaid Expenses		 2.84 4.21 3.72 1.84 2.03 2.41 2.08 0.96
Plant, Property, & Equipment, net		 0.20 0.15 0.12 0.10 0.07 0.05 0.02 0.02
Total Noncurrent Assets		 0.65 0.54 0.47 0.41 0.29 0.23 0.16 0.02
Other Noncurrent Operating Assets		 0.37 0.29 0.25 0.20 0.12 0.07 0.02 0.02
Total Liabilities & Shareholders' Equity		 58 48 43 38 29 25 22 14
Total Liabilities		 5.39 5.50 4.58 4.76 3.88 4.39 4.64 3.39
Total Current Liabilities		 5.13 5.33 4.46 4.69 3.81 4.31 4.57 3.32
Accounts Payable		 1.31 1.26 0.73 0.56 0.60 0.78 0.62 0.51
Accrued Expenses		 3.82 4.07 3.73 4.14 3.21 3.53 3.95 2.81
Total Noncurrent Liabilities		 0.25 0.16 0.12 0.07 0.07 0.07 0.07 0.07
Other Noncurrent Operating Liabilities		 0.25 0.16 0.12 0.07 0.07 0.07 0.07 0.07
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 53 43 38 33 25 21 17 11
Total Preferred & Common Equity		 53 43 38 34 25 21 17 11
Total Common Equity		 53 43 38 34 25 21 17 11
Common Stock		 576 577 578 578 579 579 580 581
Retained Earnings		 -523 -533 -539 -543 -553 -557 -562 -569
Treasury Stock		 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71
Accumulated Other Comprehensive Income / (Loss)		 -0.10 -0.10 -0.08 -0.03 -0.08 -0.05 -0.04 -0.02
Noncontrolling Interest		 -0.25 -0.25 -0.25 -0.25 -0.25 -0.25 -0.25 -0.25

Annual Metrics And Ratios for Lisata Therapeutics

This table displays calculated financial ratios and metrics derived from Lisata Therapeutics' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2025
DEI Shares Outstanding		 35,738,358.00 55,373,251.00 8,169,407.00 9,470,860.00 9,841,983.00 10,399,930.00 19,395,977.00 59,779,855.00 7,859,684.00 8,139,449.00 8,820,733.00
DEI Adjusted Shares Outstanding		 3,573,836.00 5,537,325.00 8,169,407.00 9,470,860.00 9,841,983.00 10,399,930.00 19,395,977.00 59,779,855.00 7,859,684.00 8,139,449.00 8,820,733.00
DEI Earnings Per Adjusted Shares Outstanding		 -15.35 -14.61 -4.00 2.43 -1.64 -1.86 -0.42 -0.46 -6.90 -2.56 -1.88
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 22.30% 25.36% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -42.94% -77.55% 68.93% 7.16% 40.86% -19.56% 1.47% -41.44% -114.26% 53.14% 30.11%
EBIT Growth		 -42.66% -75.36% 69.33% 7.32% 40.84% -19.73% 1.07% -52.13% -98.30% 55.17% 29.12%
NOPAT Growth		 -56.87% -97.17% 74.09% 6.47% 38.44% -18.28% 4.71% -51.74% -98.28% 55.37% 29.17%
Net Income Growth		 -40.47% -46.05% 58.88% 166.73% -172.74% -19.69% 57.93% -237.38% -97.43% 61.57% 20.41%
EPS Growth		 11.58% -46.05% 70.07% 0.00% 0.00% -12.57% 71.81% -1,305.66% -40.54% 75.36% 25.97%
Operating Cash Flow Growth		 -73.03% 16.29% 39.71% 11.80% 4.26% 5.52% 53.27% -152.13% 4.83% 5.38% 3.37%
Free Cash Flow Firm Growth		 -200.44% 25.97% 103.35% -815.21% -31.29% 6.05% -4.08% -25.66% -105.06% 54.80% 23.14%
Invested Capital Growth		 141.81% -59.29% -113.33% -270.15% 42.50% 17.77% 49.37% -27.41% 2.29% 8.99% 48.69%
Revenue Q/Q Growth		 7.16% 11.30% -100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 1.85% -58.90% 58.19% -7.61% 18.24% -6.51% -2.66% -3.40% -0.65% 1.35% 22.96%
EBIT Q/Q Growth		 1.43% -56.80% 58.23% -7.45% 18.33% -7.77% -3.04% -4.74% 0.49% 1.94% 22.70%
NOPAT Q/Q Growth		 -9.60% -63.36% 64.84% -7.92% 17.18% -6.84% -1.94% -5.07% 0.53% 1.97% 22.47%
Net Income Q/Q Growth		 1.82% -36.22% 44.90% 16.78% -4.27% -7.77% -6.25% -5.22% 1.46% 2.91% 20.03%
EPS Q/Q Growth		 -5.66% -36.22% 47.31% 0.00% -4.38% -6.21% 18.46% -211.72% 27.59% 22.99% 23.90%
Operating Cash Flow Q/Q Growth		 -8.17% 5.25% 18.44% -2.93% 4.44% -6.65% -18.02% 4.15% -9.66% 10.70% -2.43%
Free Cash Flow Firm Q/Q Growth		 -13.12% -13.22% 104.49% -181.67% 20.37% -5.12% -7.78% 3.45% -4.87% 10.62% 10.68%
Invested Capital Q/Q Growth		 4.89% -53.51% -112.10% 12.38% -4.84% -10.17% 16.21% -71.08% 22.80% -56.27% 44.01%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 12.60% 10.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00%
EBITDA Margin		 -293.37% -415.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,961.76%
Operating Margin		 -321.88% -506.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,711.18%
EBIT Margin		 -305.57% -427.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,796.47%
Profit (Net Income) Margin		 -309.20% -360.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9,756.47%
Tax Burden Percent		 99.81% 82.45% 106.56% -80.25% 100.00% 100.00% 42.82% 94.80% 95.63% 89.94% 94.52%
Interest Burden Percent		 101.38% 102.21% 106.04% 101.38% 100.03% 100.00% 99.31% 99.48% 98.18% 89.48% 95.61%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -118.00% -233.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -59.67% -213.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 25.64% 34.60% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -92.37% -199.15% -142.50% 60.36% -36.90% -66.72% -30.84% -44.21% -68.50% -36.49% -53.08%
Cash Return on Invested Capital (CROIC)		 -200.98% -149.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -50.73% -104.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -50.68%
Return on Assets (ROA)		 -51.34% -88.30% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -45.79%
Return on Common Equity (ROCE)		 -93.10% -201.28% -87.17% 45.39% -37.14% -67.34% -31.14% -44.39% -68.72% -36.65% -53.51%
Return on Equity Simple (ROE_SIMPLE)		 -94.79% -341.62% -682.03% 44.01% -42.86% -92.97% -25.05% -29.77% -81.45% -43.28% 0.00%
Net Operating Profit after Tax (NOPAT)		 -40 -80 -21 -19 -12 -14 -13 -20 -40 -18 -13
NOPAT Margin		 -225.31% -354.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,497.82%
Net Nonoperating Expense Percent (NNEP)		 -58.33% -19.99% -85.38% 96.59% -8.31% -15.50% 17.61% -11.01% -16.94% -4.75% -11.55%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - -37.57% -87.30%
Cost of Revenue to Revenue		 87.40% 89.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 171.73% 133.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6,135.29%
R&D to Revenue		 162.74% 106.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,675.88%
Operating Expenses to Revenue		 334.48% 516.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10,811.18%
Earnings before Interest and Taxes (EBIT)		 -55 -96 -29 -27 -16 -19 -19 -29 -58 -26 -18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -53 -93 -29 -27 -16 -19 -19 -27 -57 -27 -19
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.30 2.52 4.73 0.66 0.93 1.25 0.85 0.55 0.30 0.46 1.10
Price to Tangible Book Value (P/TBV)		 0.00 4.32 4.73 0.66 0.93 1.25 0.85 0.55 0.30 0.46 1.10
Price to Revenue (P/Rev)		 7.51 2.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 96.51
Price to Earnings (P/E)		 0.00 0.00 0.00 1.45 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 69.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.57 2.83 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 6.95 2.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.16
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 24.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.29 0.72 0.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.25 0.49 0.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.43 -0.16 -0.63 -1.17 -1.18 -1.18 -1.13 -1.04 -1.04 -1.05 -1.06
Leverage Ratio		 1.80 2.26 2.37 1.59 1.23 1.24 1.20 1.07 1.07 1.12 1.16
Compound Leverage Factor		 1.82 2.31 2.51 1.61 1.23 1.24 1.19 1.07 1.05 1.00 1.11
Debt to Total Capital		 22.27% 41.88% 21.36% 0.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 2.58% 13.39% 12.37% 0.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 19.70% 28.49% 8.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -0.59% -1.07% 62.27% -0.63% -0.73% -1.28% -0.79% -0.28% -0.38% -0.53% -1.74%
Common Equity to Total Capital		 78.32% 59.20% 16.37% 100.32% 100.73% 101.28% 100.79% 100.28% 100.38% 100.53% 101.74%
Debt to EBITDA		 -0.32 -0.18 -0.22 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.18 0.04 0.02 2.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.28 -0.12 -0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.41 -0.21 -0.31 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.24 0.04 0.03 3.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.36 -0.14 -0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -3.14 -13.03 -11.87 -7.36 -9.71 -20.62 -12.82 -0.37 -9.48 -12.08 -43.83
Noncontrolling Interest Sharing Ratio		 -0.80% -1.07% 38.83% 24.80% -0.67% -0.92% -0.98% -0.41% -0.32% -0.44% -0.81%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.23 1.39 1.16 6.59 7.85 4.35 10.08 21.27 11.26 8.18 5.76
Quick Ratio		 1.81 1.09 0.34 5.91 7.66 4.21 9.86 21.00 10.85 7.67 5.20
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -69 -51 1.71 -12 -16 -15 -16 -20 -40 -18 -14
Operating Cash Flow to CapEx		 -1,282.22% -1,232.32% -2,152.66% -15,463.70% 0.00% 0.00% -44,115.00% -37,075.00% -7,428.07% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -91.09 -23.94 0.96 -32.30 -3,205.78 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -62.06 -18.44 -13.30 -55.23 -3,997.20 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -66.90 -19.94 -13.92 -55.58 -3,514.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.17 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 7.22 7.92 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.25 1.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.76
Accounts Payable Turnover		 3.48 4.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 50.58 46.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 104.95 88.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -54.37 -42.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 48 20 -2.63 -9.74 -5.60 -4.60 -2.33 -2.97 -2.90 -2.64 -1.36
Invested Capital Turnover		 0.52 0.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.09
Increase / (Decrease) in Invested Capital		 28 -29 -22 -7.11 4.14 1.00 2.27 -0.64 0.07 0.26 1.29
Enterprise Value (EV)		 125 56 41 -27 -8.29 0.68 -7.09 -45 -50 -29 0.20
Market Capitalization		 135 60 23 33 35 26 28 50 20 22 16
Book Value per Share		 $1.64 $0.43 $0.60 $5.33 $3.83 $2.00 $1.68 $1.54 $8.47 $5.92 $1.68
Tangible Book Value per Share		 ($0.40) $0.25 $0.60 $5.33 $3.83 $2.00 $1.68 $1.54 $8.43 $5.88 $1.68
Total Capital		 75 40 30 50 37 21 32 92 66 48 15
Total Debt		 17 17 6.37 0.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 15 11 2.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -9.61 -3.54 -0.70 -60 -43 -25 -35 -95 -69 -51 -16
Capital Expenditures (CapEx)		 3.66 3.19 1.10 0.14 -2.42 0.00 0.02 0.06 0.29 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.29 -6.70 0.08 -7.84 -4.57 -5.16 -2.75 -3.31 -3.73 -3.20 -1.32
Debt-free Net Working Capital (DFNWC)		 22 14 7.16 52 38 20 32 92 65 47 15
Net Working Capital (NWC)		 20 8.26 3.47 52 38 20 32 92 65 47 15
Net Nonoperating Expense (NNE)		 15 1.32 13 -42 4.28 5.29 -5.26 7.13 14 2.84 3.84
Net Nonoperating Obligations (NNO)		 -9.61 -3.56 -26 -60 -43 -25 -35 -95 -69 -51 -16
Total Depreciation and Amortization (D&A)		 2.19 2.69 0.45 0.37 0.23 0.30 0.37 2.57 0.86 -0.77 -0.28
Debt-free, Cash-free Net Working Capital to Revenue		 -23.92% -29.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -778.82%
Debt-free Net Working Capital to Revenue		 122.44% 60.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8,607.06%
Net Working Capital to Revenue		 111.70% 36.72% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8,607.06%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($16.80) ($16.70) ($4.99) $2.56 ($1.67) ($1.88) ($0.53) ($0.50) ($10.47) ($2.58) ($1.91)
Adjusted Weighted Average Basic Shares Outstanding		 3.85M 5.90M 8.31M 8.97M 9.69M 10.64M 59.51M 55.31M 5.18M 8.07M 8.69M
Adjusted Diluted Earnings per Share		 ($16.80) ($16.70) ($4.99) $2.56 $0.00 ($1.88) ($0.53) ($0.50) ($10.47) ($2.58) ($1.91)
Adjusted Weighted Average Diluted Shares Outstanding		 3.85M 5.90M 8.31M 8.97M 9.69M 10.64M 59.51M 55.31M 5.18M 8.07M 8.69M
Adjusted Basic & Diluted Earnings per Share		 ($16.80) ($16.70) ($4.99) $0.00 $0.00 ($1.88) ($0.53) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 3.28M 4.85M 6.55M 9.55M 9.95M 10.33M 15.44M 60.53M 8.00M 8.31M 9.03M
Normalized Net Operating Profit after Tax (NOPAT)		 -40 -36 -21 -19 -12 -14 -13 -20 -40 -18 -13
Normalized NOPAT Margin		 -225.31% -160.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,497.82%
Pre Tax Income Margin		 -309.78% -436.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,322.35%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -72.54 -45.16 -16.56 -72.28 -3,232.60 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -53.49 -37.44 -11.60 -51.10 -2,378.18 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -77.38 -46.66 -17.18 -72.63 -2,749.40 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -58.32 -38.94 -12.22 -51.46 -1,894.98 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 45.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 45.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Lisata Therapeutics

This table displays calculated financial ratios and metrics derived from Lisata Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2025 3/31/2025 6/30/2025 9/30/2025 3/31/2026
DEI Shares Outstanding		 7,974,464.00 8,139,449.00 8,307,433.00 8,307,433.00 8,319,600.00 8,820,733.00 8,620,162.00 8,598,204.00 8,755,948.00 9,032,291.00
DEI Adjusted Shares Outstanding		 7,974,464.00 8,139,449.00 8,307,433.00 8,307,433.00 8,319,600.00 8,820,733.00 8,620,162.00 8,598,204.00 8,755,948.00 9,032,291.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.66 -0.66 -0.65 -0.61 -0.59 -0.14 -0.55 -0.54 -0.49 -0.50
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 83.53% 5.53% 1.18% 22.27% 12.57% 94.65% 13.69% 13.76% 18.93% 16.07%
EBIT Growth		 84.16% 7.80% 1.01% 21.18% 9.94% 89.27% 12.32% 11.96% 17.64% 16.06%
NOPAT Growth		 84.19% 7.89% 3.55% 19.67% 10.53% 87.57% 11.42% 11.86% 17.28% 15.48%
Net Income Growth		 85.93% 10.43% 12.70% -25.25% 6.29% 77.43% 12.53% 7.63% 13.81% 4.97%
EPS Growth		 91.75% 53.85% 15.58% -22.00% 9.23% 90.91% 15.38% 11.48% 16.95% 9.09%
Operating Cash Flow Growth		 10.38% 37.09% 14.26% -26.27% 29.72% 72.45% 23.13% 25.12% -32.72% 42.93%
Free Cash Flow Firm Growth		 74.39% 3.62% 5.78% 36.48% 51.87% 59.58% 9.96% 31.11% -20.82% 54.58%
Invested Capital Growth		 55.04% 8.99% -54.59% 0.00% -43.20% 48.69% -20.63% -347.57% 22.36% -226.68%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% -100.00% 0.00%
EBITDA Q/Q Growth		 14.18% -0.48% -10.46% 18.41% 3.47% 93.85% -1,681.44% 18.47% 9.26% 0.00%
EBIT Q/Q Growth		 14.95% -1.04% -12.44% 18.43% 2.82% 87.96% -818.52% 18.09% 9.09% 0.00%
NOPAT Q/Q Growth		 13.25% -1.02% -9.56% 16.33% 3.39% 85.96% -680.64% 16.74% 9.33% 0.00%
Net Income Q/Q Growth		 -30.64% -1.98% -0.67% 6.61% 2.26% 75.44% -290.09% 1.38% 8.80% 0.00%
EPS Q/Q Growth		 -30.00% -1.54% 1.52% 6.15% 3.28% 89.83% -816.67% 1.82% 9.26% 0.00%
Operating Cash Flow Q/Q Growth		 14.36% -13.56% -72.70% 24.82% 52.34% 55.48% -381.89% 26.77% 15.52% 0.00%
Free Cash Flow Firm Q/Q Growth		 -10.19% 28.27% 1.60% 18.33% 16.50% 39.76% -119.18% 37.51% -46.43% 0.00%
Invested Capital Q/Q Growth		 0.00% -56.27% 77.05% 55.94% -806.37% 44.01% 46.05% -63.47% -57.24% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 100.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -196.47% 0.00% -6,930.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -440.59% 0.00% -6,954.29% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -381.18% 0.00% -6,964.29% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -712.35% 0.00% -6,655.71% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 87.13% 100.00% 100.00% 88.07% 83.08% 100.00% 100.00% 92.06%
Interest Burden Percent		 88.05% 88.87% 91.32% 91.10% 91.62% 212.19% 95.53% 95.57% 95.87% 97.60%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -34.49% -36.49% -38.77% -55.46% -48.15% -53.08% -46.90% -64.40% -72.17% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -1.79% 0.00% -220.04% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -3.34% 0.00% -210.29% 0.00% 0.00%
Return on Common Equity (ROCE)		 -34.63% -36.65% -38.96% -55.83% -48.44% -53.51% -47.25% -64.95% -72.89% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -40.53% 0.00% -46.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.17 -4.22 -4.62 -3.87 -3.74 -0.52 -4.09 -3.41 -3.09 -3.46
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -308.41% 0.00% -4,868.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.67% -1.92% -1.49% -6.16% -2.65% -2.07% -1.82% -4.16% -4.23% -5.29%
Return On Investment Capital (ROIC_SIMPLE)		 - -8.81% -10.81% -10.18% -11.17% -3.59% -16.31% -16.40% -18.05% -32.42%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 796.47% 0.00% 3,835.71% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -255.88% 0.00% 3,218.57% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 540.59% 0.00% 7,054.29% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -5.98 -6.04 -6.79 -5.54 -5.38 -0.65 -5.95 -4.88 -4.43 -5.00
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.21 -6.24 -6.89 -5.63 -5.43 -0.33 -5.95 -4.85 -4.40 -4.99
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.32 0.46 0.60 0.75 0.74 1.10 0.80 1.19 1.32 4.14
Price to Tangible Book Value (P/TBV)		 0.32 0.46 0.61 0.76 0.75 1.10 0.80 1.19 1.33 4.14
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 96.51 119.16 23.30 21.44 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 1.16 0.00 2.53 3.45 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 19.27
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.05 -1.01 -1.01 -1.05 -1.06 -1.02 -1.02 -1.09 -1.09
Leverage Ratio		 1.10 1.12 1.11 1.12 1.12 1.16 1.14 1.15 1.19 1.20
Compound Leverage Factor		 0.97 0.99 1.01 1.02 1.02 2.46 1.09 1.10 1.14 1.17
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -0.48% -0.53% -0.59% -0.67% -0.76% -1.74% -1.01% -1.22% -1.48% -2.38%
Common Equity to Total Capital		 100.48% 100.53% 100.59% 100.67% 100.76% 101.74% 101.01% 101.22% 101.48% 102.38%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -9.96 -10.88 -12.07 -13.30 -16.20 -40.54 -23.22 -27.22 -32.86 -48.92
Noncontrolling Interest Sharing Ratio		 -0.41% -0.44% -0.49% -0.67% -0.59% -0.81% -0.75% -0.86% -1.00% -1.42%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 11.15 8.18 8.92 9.42 8.04 5.76 7.52 5.77 4.72 4.23
Quick Ratio		 10.60 7.67 8.13 8.58 7.64 5.20 6.98 5.21 4.27 3.94
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.24 -4.48 -4.41 -3.60 -3.01 -1.81 -3.97 -2.48 -3.63 -1.80
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% -4,003.57% -19,292.86% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.04 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 1.76 1.55 12.81 18.14 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -1.69 -2.64 -0.61 -0.27 -2.42 -1.36 -0.73 -1.20 -1.88 -2.39
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 -0.09 -0.25 -1.46 -0.50 0.00
Increase / (Decrease) in Invested Capital		 2.07 0.26 -0.21 -0.27 -0.73 1.29 -0.13 -0.93 0.54 -1.66
Enterprise Value (EV)		 -38 -29 -18 -9.69 -11 0.20 -5.83 2.70 3.69 32
Market Capitalization		 17 22 26 29 25 16 20 25 23 45
Book Value per Share		 $6.64 $5.92 $5.18 $4.60 $4.05 $1.68 $2.94 $2.45 $1.98 $1.21
Tangible Book Value per Share		 $6.61 $5.88 $5.15 $4.58 $4.02 $1.68 $2.92 $2.43 $1.97 $1.21
Total Capital		 53 48 43 38 33 15 25 21 17 11
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -54 -51 -43 -38 -36 -16 -26 -22 -19 -13
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.03 0.03 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.29 -3.20 -1.12 -0.74 -2.86 -1.32 -1.02 -1.40 -1.99 -2.36
Debt-free Net Working Capital (DFNWC)		 52 47 42 38 33 15 25 21 17 11
Net Working Capital (NWC)		 52 47 42 38 33 15 25 21 17 11
Net Nonoperating Expense (NNE)		 1.09 1.15 0.78 1.18 1.19 0.69 0.63 1.25 1.16 1.03
Net Nonoperating Obligations (NNO)		 -54 -51 -43 -38 -36 -16 -26 -22 -19 -13
Total Depreciation and Amortization (D&A)		 -0.24 -0.20 -0.11 -0.09 -0.05 0.31 0.00 0.02 0.03 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -778.82% -601.76% -130.65% -186.07% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 8,607.06% 14,594.12% 1,922.62% 1,589.44% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 8,607.06% 14,594.12% 1,922.62% 1,589.44% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.65) ($0.66) ($0.65) ($0.61) ($0.59) ($0.06) ($0.55) ($0.54) ($0.49) ($0.50)
Adjusted Weighted Average Basic Shares Outstanding		 8.14M 8.07M 8.29M 8.31M 8.32M 8.69M 8.60M 8.61M 8.74M 9.01M
Adjusted Diluted Earnings per Share		 ($0.65) ($0.66) ($0.65) ($0.61) ($0.59) ($0.06) ($0.55) ($0.54) ($0.49) ($0.50)
Adjusted Weighted Average Diluted Shares Outstanding		 8.14M 8.07M 8.29M 8.31M 8.32M 8.69M 8.60M 8.61M 8.74M 9.01M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 8.14M 8.31M 8.31M 8.32M 8.39M 9.03M 8.60M 8.76M 8.82M 9.11M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.17 -4.22 -4.62 -3.87 -3.74 -0.52 -4.09 -3.41 -3.09 -3.46
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -308.41% 0.00% -4,868.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -808.82% 0.00% -6,655.71% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Lisata Therapeutics (NASDAQ: LSTA) remains a pre-revenue biotechnology company with no product sales reported in the periods provided. Over the last four years, the story has been less about growth in revenue and more about cash preservation, operating losses, and balance sheet changes tied to financing and investment activity.

  • The company still had $13.1 million in cash and equivalents at the end of Q1 2026, giving it some liquidity despite continued losses.
  • Lisata has consistently generated investment income, which helped offset a portion of operating losses in several quarters.
  • R&D spending has come down sharply from earlier levels, with Q1 2026 R&D at $1.2 million versus $3.2 million in Q1 2024, suggesting tighter cost control.
  • Operating cash burn improved in the latest quarter versus the prior-year comparison, with Q1 2026 operating cash outflow of $3.1 million compared with $5.4 million in Q1 2025.
  • The company has used its investment portfolio to support liquidity at times, including meaningful investment sales in prior periods.
  • Revenue remains essentially absent, with no revenue in Q1 2026 and only small, inconsistent revenue amounts in some 2025 and 2024 quarters.
  • The share count has drifted upward over time, with basic shares outstanding rising from about 8.3 million in Q1 2024 to 9.0 million in Q1 2026, which can dilute shareholders.
  • Balance sheet liabilities are modest relative to assets, with $3.4 million in total liabilities versus $14.1 million in total assets in Q1 2026.
  • The company’s equity base has been reduced by cumulative losses, reflected in negative retained earnings of -$569.1 million in Q1 2026.
  • Lisata continues to post large quarterly net losses, including -$4.5 million in Q1 2026 and -$4.7 million in Q1 2025.
  • Operating losses remain substantial, with Q1 2026 operating loss of $4.9 million on no revenue.
  • Cash declined materially over the last year, falling from $20.2 million in Q1 2025 to $13.1 million in Q1 2026.
  • The company has been cash-flow negative from operations every quarter shown, indicating ongoing dependence on financing, asset sales, or prior cash reserves.
  • The longer-term trend is still one of persistent shareholder dilution and cumulative losses, which is common in development-stage biotech but remains a risk for investors.

In short, Lisata Therapeutics is still in a high-risk, cash-burning development phase. The latest quarter shows some improvement in operating cash usage and lower R&D spending, but the company remains unprofitable, revenue-light, and dependent on its cash balance to fund operations.

07/25/26 10:27 AM ETAI Generated. May Contain Errors.

Lisata Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Lisata Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

Lisata Therapeutics' net income appears to be on a downward trend, with a most recent value of -$19.99 million in 2024, falling from -$55.47 million in 2014. The previous period was -$20.84 million in 2023. Find out what analysts predict for Lisata Therapeutics in the coming months.

Lisata Therapeutics' total operating income in 2024 was -$22.41 million, based on the following breakdown:
  • Total Gross Profit: $1 million
  • Total Operating Expenses: $23.41 million

Over the last 10 years, Lisata Therapeutics' total revenue changed from $17.94 million in 2014 to $1 million in 2024, a change of -94.4%.

Lisata Therapeutics' total liabilities were at $3.14 million at the end of 2025, which was unchanged from 2024, and a 90.7% decrease since 2015.

In the past 10 years, Lisata Therapeutics' cash and equivalents has ranged from $7.08 million in 2016 to $32.15 million in 2022, and is currently $15.96 million as of their latest financial filing in 2025.

Over the last 10 years, Lisata Therapeutics' book value per share changed from 1.64 in 2014 to 1.68 in 2024, a change of 2.9%.


Related Companies

Financial statements for NASDAQ:LSTA last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel